Author(s): Dewan NA, Nieto FJ, Somers VK
Abstract Share this page
Abstract OSA is a common chronic disorder that is associated with significant morbidity and mortality including cardiovascular, metabolic, and neurocognitive disease and increased cancer-related deaths. OSA is characterized by recurrent episodes of apneas and hypopneas associated with repetitive episodes of intermittent hypoxemia, intrathoracic pressure changes, and arousals. Intermittent hypoxemia (IH) is now being recognized as a potential major factor contributing to the pathogenesis of OSA-related comorbidities. OSA-related high-frequency IH is characterized by cycles of hypoxemia with reoxygenation that is distinctly different than sustained low-frequency hypoxia and contributes to ischemia-reperfusion injury. Data from both animal and human studies support mechanistic links between IH and its adverse impact at the tissue level. IH promotes oxidative stress by increased production of reactive oxygen species and angiogenesis, increased sympathetic activation with BP elevation, and systemic and vascular inflammation with endothelial dysfunction that contributes to diverse multiorgan chronic morbidity and mortality affecting cardiovascular disease, metabolic dysfunction, cognitive decline, and progression of cancer. Data from observational studies in large population groups also support the role for hypoxia in the pathogenesis of OSA comorbidity. Treatment with CPAP to reverse OSA-related symptoms and comorbidities has been shown to provide variable benefit in some but not all patient groups. Early treatment with CPAP makes intuitive sense to promote maximal functional recovery and minimize residual injury. More studies are needed to determine the interacting effects of IH and obesity, differential effects of both short-term and long-term hypoxemia, and the effect of CPAP treatment.
This article was published in Chest
and referenced in Journal of Thyroid Disorders & Therapy
- Ildiko Molnar
The role of tissue-specific type 2 5â-deiodinase enzyme activities in Gravesâ orbitopathy and systemic sclerosis: a new candidate in thyroid autoimmunity
- Ildikó Molnár
Characteristics of allergy in autoimmune thyroid diseases
PPT Version | PDF Version
- Paul J. Davis
Nanotetrac targets the thyroid hormone receptor on integrin Î±vÎ²3 on tumor cells to promote apoptosis, disorder cell defense pathways and block angiogenesis
PPT Version | PDF Version
- A Martin Gerdes
Wrong about Î²-blockers! Wrong about positive inotropes! Wrong about Thyroid Hormone treatment of Heart Failure?